Affordable Access

deepdyve-link
Publisher Website

Pyoderma gangrenosum: Classic and emerging therapies.

Authors
  • Soto Vilches, Felipe1
  • Vera-Kellet, Cristián2
  • 1 Departamento de Dermatología, Hospital Clínico Universidad de Chile, Santiago, Chile. , (Chile)
  • 2 Departamento de Dermatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address: [email protected] , (Chile)
Type
Published Article
Journal
Medicina Clínica
Publisher
Elsevier
Publication Date
Sep 20, 2017
Volume
149
Issue
6
Pages
256–260
Identifiers
DOI: 10.1016/j.medcli.2017.04.013
PMID: 28629662
Source
Medline
Keywords
License
Unknown

Abstract

Pyoderma gangrenosum is an ulceronecrotising dermatosis that represents a challenge for any clinician, not only for its ability to mimic other dermatoses but also for its lack of response to treatment. During the past year, there have been new studies about the efficacy of standard therapies, such as cyclosporine and systemic corticosteroids. These studies showed that classic treatment was comparable, but they are insufficient as monotherapy. That being said, new emerging therapies are becoming important, as the use of corticosteroid-sparing agents, tumour necrosis factor inhibitors or even surgery. This review updates the current evidence for the treatment of pyoderma gangrenosum.

Report this publication

Statistics

Seen <100 times